Evolent Health (EVH) Expected to Announce Earnings on Tuesday

Evolent Health (NYSE:EVH) is projected to announce its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect Evolent Health to post earnings of $0.06 per share and revenue of $468.4810 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, February 24, 2026 at 5:00 PM ET.

Evolent Health Stock Performance

Shares of EVH opened at $2.79 on Friday. The company has a market cap of $310.81 million, a price-to-earnings ratio of -1.76 and a beta of 0.27. The business’s fifty day simple moving average is $3.59 and its two-hundred day simple moving average is $5.99. Evolent Health has a 12 month low of $2.56 and a 12 month high of $12.06. The company has a current ratio of 1.33, a quick ratio of 1.33 and a debt-to-equity ratio of 1.25.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on EVH shares. Canaccord Genuity Group reduced their target price on shares of Evolent Health from $16.00 to $9.00 and set a “buy” rating on the stock in a research note on Friday, November 14th. Citigroup reduced their price objective on shares of Evolent Health from $9.50 to $6.00 and set a “buy” rating on the stock in a research report on Friday, January 9th. Zacks Research upgraded Evolent Health from a “strong sell” rating to a “hold” rating in a research report on Monday, November 10th. Truist Financial cut their target price on Evolent Health from $16.00 to $10.00 and set a “buy” rating on the stock in a research note on Monday, November 10th. Finally, Piper Sandler set a $6.00 price target on Evolent Health in a report on Tuesday, December 2nd. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $9.50.

Hedge Funds Weigh In On Evolent Health

A number of hedge funds have recently added to or reduced their stakes in EVH. Brighton Jones LLC bought a new stake in shares of Evolent Health during the fourth quarter valued at approximately $3,927,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Evolent Health by 2.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 128,527 shares of the technology company’s stock worth $1,217,000 after purchasing an additional 3,572 shares during the period. Goldman Sachs Group Inc. raised its position in Evolent Health by 162.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,836,402 shares of the technology company’s stock valued at $26,861,000 after purchasing an additional 1,754,520 shares in the last quarter. Caxton Associates LLP purchased a new stake in shares of Evolent Health in the 1st quarter worth $252,000. Finally, Strs Ohio purchased a new stake in shares of Evolent Health in the 1st quarter worth $47,000.

About Evolent Health

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.